Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat for Uncontrolled or Resistant Hypertension (BaxHTN)
jRCT2031230558Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of baxdrostat in hypertension (HTN) and resistant hypertension (RH) (3 arms), sponsored by AstraZeneca. Primary endpoints: Change from baseline in seated systolic blood pressure for 2 mg baxdrostat at Week 12 and Change from baseline in seated systolic blood pressure for 1 mg baxdrostat at Week 12. Started Jan 2024; status: completed.
02
Drugs
baxdrostat
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on jRCT2031230558.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230558.